gyrA Mutations in high-level fluoroquinolone-resistant clinical isolates of Escherichia coli

Journal of Antimicrobial Chemotherapy

Volumn 38, Issue 3, 1996, Pages 443-455

  Conrad, S ^a   Oethinger, M ^a,b   Kaifel, K ^a   Klotz, G ^a   Marre, R ^a   Kern, W V ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; CODON; CONTROLLED STUDY; ESCHERICHIA COLI; GENE MUTATION; GENOTYPE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; PULSED FIELD GEL ELECTROPHORESIS;

ANTI-INFECTIVE AGENTS; DNA GYRASE; DNA TOPOISOMERASES, TYPE II; DRUG RESISTANCE, MICROBIAL; ESCHERICHIA COLI; EUROPE; HUMANS; MICROBIAL SENSITIVITY TESTS; MIDDLE EAST; MUTATION; NALIDIXIC ACID; OFLOXACIN; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA; VARIATION (GENETICS);

EID: 0029819363     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/38.3.443     Document Type: Article

References (57)

1. Alangaden, G. J., Manavathu, E. K., Vakulenko, S. B., Zvonok, N. M. & Lerner, S. A. (1995). Characterization of fluoroquinolone-resistant mutant strains of Mycobacterium tuberculosis selected in the laboratory and isolated from patients. Antimicrobial Agents and Chemotherapy 39, 1700-3.
2. Alarcón, T., Pita, J., Lopez-Bréa, M. & Piddock, L. J. (1993). High-level quinolone resistance amongst clinical isolates of Escherichia coli and Klebsiella pneumoniae from Spain. Journal of Antimicrobial Chemotherapy 32, 605-9.
3. Aoyama, H., Sato, K., K.ato, T., Hirai, K. & Mitsuhashi, S. (1987). Norfloxacin resistance in a clinical isolate of Escherichia coli. Antimicrobial Agents and Chemotherapy 31, 1640-1.
4. Arduino, S., Veron, T., Villar, H. & Dictar, M. (1992). Rapid increase of resistance to fluoroquinolones (FQ) in clinical isolates of Escherichia coli. In Program and Abstracts of the Thirty-Second Interscience Conference of Antimicrobial Agents and Chemotherapy, Anaheim, 1992. Abstract 635, p.216. American Society for Microbiology, Washington, DC.
5. Cambau, E., Sougakoff, W., Besson, M., Truffot-Pernot, C., Grosset, J. & Jarlier, V. (1994). Selection of a gyrA mutant of Mycobacterium tuberculosis resistant to fluoroquinolones during treatment with ofloxacin. Journal of Infectious Diseases 170, 479-83.
6. Carratalá, J., Fernandez-Sevilla, A., Tubau, F., Callis, M. & Gudiol, F. (1995). Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clinical Infectious Diseases 20, 557-60.
7. Cometta, A., Calandra, T., Bille, J. & Glauser, M. P. (1994). Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia. New England Journal of Medicine 330, 1240-1.
8. Cometta, A., Zinner, S., de Bock, R., Calandra, T., Gaya, H., Klastersky, J. et al. (1995). Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrobial Agents and Chemotherapy 39, 445-52.
9. Cullen, M. E., Wyke, A. W., Kuroda, R. & Fisher, L. M. (1989). Cloning and characterization of a DNA gyrase A gene from Escherichia coli that confers clinical resistance to 4-quinolones. Antimicrobial Agents and Chemotherapy 33, 886-94.
10. EORTC International Antimicrobial Therapy Cooperative Group & GIMEMA Infection Program (1995). Meropenem versus ceftazidime plus amikacin as empirical therapy for fever in cancer patients with granulocytopenia. In Program and Abstracts of the 19th International Congress in Chemotherapy, Montréal, 1995. Abstract 1083.
11. Farmer, J. J. & Kelly, M. T. (1991). Enterobacteriaceae. In Manual of Clinical Microbiology, 5th edn (Balows, A., Hausler, J. H., Herrmann, K. L., Isenberg, H. D. & Shadomy, H. J., Eds), pp. 360-83. American Society for Microbiology, Washington, DC.
12. Ferrero, L., Cameron, B. & Crouzet, J. (1995). Analysis of gyrA and gyrA mutations in step-wise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 39, 1554-8.
13. Goswitz, J. J., Willard, K. E., Fasching, C. E. & Peterson, L. R. (1992). Detection of gyrA gene mutations associated with ciprofloxacin resistance in methicillin-resistant Staphylococcus aureus: analysis by polymerase chain reaction and direct DNA sequencing. Antimicrobial Agents and Chemotherapy 36, 1166-9.
14. Heisig, P., Schedlitzky, H. & Falkenstein-Paul, H. (1993). Mutations in the gyrA gene of a high-level fluoroquinolone-resistant clinical isolate of Escherichia coli. Antimicrobial Agents and Chemotherapy 37, 696-701.
15. Heisig, P. & Tschorny, R. (1994). Characterization of fluoroquinolone-resistant mutants of Escherichia coli selected in vitro. Antimicrobial Agents and Chemotherapy 38, 1284-91.
16. Hooper, D. C. & Wolfson, J. (1985). The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans. Antimicrobial Agents and Chemotherapy 28, 716-21.
17. Hoshino, K., Kitamura, A., Morrissey, I., Sato, K., Kato, J.-I. & Ikeda, H. (1994). Comparison of inhibition of Escherichia coli topoisomerase IV by quinolones with DNA gyrase inhibition. Antimicrobial Agents and Chemotherapy 38, 2623-7.
18. Ito, H., Yoshida, H., Bogaki-Shonai, M., Niga, T., Hattori, H. & Nakamura, S. (1994). Quinolone resistance mutations in the DNA gyrase gyrA and gyrB genes of Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 38, 2014-23.
19. Jonsson, M., Walder, M. & Forsgren, A. (1990). First clinical isolate of highly fluoroquinolone-resistant Escherichia coli in Scandinavia. European Journal of Clinical Microbiology and Infectious Diseases 9, 851-3.
20. Kern, W. V., Andriof, E., Oethinger, M., Kern, P., Hacker, J. & Marre, R. (1994a). Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrobial Agents and Chemotherapy 38, 681-7.
21. Kern, W. V., Markus, A. & Andriof, E. (19946). Bacteremia due to fluoroquinolone-resistant Escherichia coli in two immunocompromised patients. European Journal of Clinical Microbiology and Infectious Diseases 13, 161-5.
22. Khodursky, A. B., Zechiedrich, E. L. & Cozzarelli, N. R. (1995). Topoisomerase IV is a target of quinolones in Escherichia coli. Proceedings of the National Academy of Science of the USA 92, 11801-5.
23. Kresken, M., Hafner, D., Mittermayer, H., Verbist, L., Bergogne-Berezin, E., Giamarellou, H. et al. (1994). Prevalence of fluoroquinolone resistance in Europe. Infection 22, Suppl. 2, S90-8.
24. Kresken, M. & Wiedemann, B. (1988). Development of resistance to nalidixic acid and the fluoroquinolones after the introduction of norfloxacin and ofloxacin. Antimicrobial Agents and Chemotherapy 32, 1285-8.
25. Kureishi, A., Diver, J. M., Beckthold, B., Schollaardt, T. & Bryan, L. E. (1994). Cloning and nucleotide sequence of Pseudomonas aeruginosa DNA gyrase gyrA gene from strain PAO1 and quinolone-resistant clinical isolates. Antimicrobial Agents and Chemotherapy 38, 1944-52.
26. Lewin, C. S., Smith, J. T., Hamilton-Miller, J. M. T. & Brumfitt, W. (1988). Gain of antibiotic sensitivity accompanying emergence of clinical ciprofloxacin resistance. Lancet i, 1462-3.
27. Linhardt, F., Ziebuhr, W., Meyer, P., Witte, W. & Hacker, J. (1992). Pulsed-field gel electrophoresis of genomic restriction fragments as a tool for the epidemiological analysis of Staphylococcus aureus and coagulase-negative staphylococci. FEMS Microbiology Letters 74, 181-7.
28. Lopez-Brea, M. & Alarcón, T. (1990). Isolation of fluoroquinolone-resistant Escherichia coli and Klebsiella pneumoniae from an infected Hickman catheter. European Journal of Clinical Microbiology and Infectious Diseases 9, 345-7.
29. Lopez-Brea, M., Arranz, R., Somolinos, N., Del Rey, M. C. & Jimenez, M. L. (1992). Escherichia coli clinical isolates resistant to fluoroquinolones from immunocompromised patients. In Program and Abstracts of the Thirty-Second Interscience Conference of Antimicrobial Agents and Chemotherapy, Anaheim, 1992. Abstract 634, p. 216. American Society for Microbiology, Washington, DC.
30. Mirelis, B., Miro, E., Navarro, F., Ogalla, C. A., Bonal, J. & Prats, G. (1993). Increased resistance to quinolones in Catalonia, Spain. Diagnostic Microbiology and Infectious Diseases 16, 137-9.
31. Nakamura, S., Nakamura, M., Kojima, K. & Yoshida, H. (1989). gyrA and gyrB mutations in quinolone-resistant strains of Escherichia coli. Antimicrobial Agents and Chemotherapy 33, 254-5.
32. National Committee for Clinical Laboratory Standards. (1990). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically-Second Edition: Approved Standard MI-AI. NCCLS, Villanova, PA.
33. Navarro, F., Miro, E., Izquierdo, C., Mirelis, B. & Prats, G. (1993). Increased resistance of enteropathogens to fluoroquinolones in Barcelona, Spain. European Journal of Clinical Microbiology and Infectious Diseases 12, 645-6.
34. Oethinger, M., Conrad, S., Haussier, K., Cometta, A., Bille, J., Calandra, T. et al. (1995). Fluoroquinolone-resistant Escherichia coli isolates from European cancer centers: genotypes and phenotypes. In Program and Abstracts of the Thirty-Fifth Interscience Conference of Antimicrobial Agents and Chemotherapy, San Francisco, 1995. Abstract 2319. American Society for Microbiology, Washington, DC.
35. Oram, M. & Fisher, L. M. (1991). 4-Quinolone resistance mutations in the DNA gyrase of Escherichia coli clinical isolates identified by using the polymerase chain reaction. Antimicrobial Agents and Chemotherapy 35, 387-9.
36. Ouabdesselam, S., Hooper, D. C., Tankovic, J. & Soussy, C. J. (1995). Detection of gyrA and gyrB mutations in quinolone-resistant clinical isolates of Escherichia coli by singlestrand conformational polymorphism analysis and determination of levels of resistance conferred by two different single gyrA mutations. Antimicrobial Agents and Chemotherapy 39, 1667-70.
37. Pena, C., Albareda, J. M., Pallares, R., Pujol, M., Tubau, F. & Ariza, J. (1995). Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections. Antimicrobial Agents and Chemotherapy 39, 520-4.
38. Perez-Trallero, E., Urbieta, M., Jimenez, D., Garcia-Arenzana, J. M. & Cilla, G. (1993). Ten-year survey of quinolone resistance in Escherichia coli causing urinary tract infections. European Journal of Clinical Microbiology and Infectious Diseases 12, 349-51.
39. Rahman, M., Mauff, G., Levy, J., Couturier, M., Pulverer, G., Glasdorff, N. et al. (1994). Detection of 4-quinolone resistance mutation in gyrA gene of Shigella dysenteriae type 1 by PCR. Antimicrobial Agents and Chemotherapy 38, 2488-91.
40. Reyna, F., Huesca, M., Gonzalez, V. & Fuchs, Y. L. (1995). Salmonella lyphimurium gyrA mutations associated with fluoroquinolone resistance. Antimicrobial Agents and Chemotherapy 39, 1621-3.
41. Richard, P., Delangle, M. H., Merrien, D., Barille, S., Reynaud, A., Minozzi, C. et al. (1994). Fluoroquinolone use and fluoroquinolone resistance: is there an association? Clinical Infectious Diseases 19, 54-9.
42. Rodriguez-Creixems, M., Diaz, M. D., Muñoz, P., Baraia, J., Cercenado, E. & Bouza, E. (1991). Emergence of clinical isolates of Escherichia coli resistant to ciprofloxacin. In Program and Abstracts of the Thirty-First Interscience Conference of Antimicrobial Agents and Chemotherapy, Chicago, 1991. Abstract 138, p. 121. American Society for Microbiology, Washington, DC.
43. Sanger, F., Nickten, S. & Coulson, A. R. (1977). DNA sequencing with chain-termination inhibitors. Proceedings of the National Academy of Sciences of the USA 74, 5463-7.
44. Sato, K., Inoue, Y., Fujii, T., Aoyama, H., Inoue, M. & Mitsuhashi, S. (1986). Purification and properties of DNA gyrase from a fluoroquinolone-resistant strain of Escherichia coli. Antimicrobial Agents and Chemotherapy 30, 777-80.
45. Soussy, C. J., Truong, Q. C., Ouabdesselam, S., Hooper, D. C. & Moreau, N. J. (1994). Sequential mutations of gyrA in Escherichia coli associated with quinolone therapy. In Program and Abstracts of the Thirty-Fourth Interscience Conference of Antimicrobial Agents and Chemotherapy, Orlando, 1994. Abstract C82, p. 101. American Society for Microbiology, Washington, DC.
46. Sreedharan, S., Oram, M., Jensen, B., Petersen, L. R. & Fisher, L. M. (1990). DNA gyrase gyrA mutations in ciprofloxacin-resistant strains of Staphylococcus aureus: close similarity with quinolone resistance mutations in Escherichia coli. Journal of Bacteriology 172, 7260-2.
47. Swanberg, S. L. & Wang, J. C. (1987). Cloning and sequencing of the Escherichia coli gyrA gene coding for the A subunit of DNA gyrase. Journal of Molecular Biology 197, 729-36.
48. Takenouchi, T., Ishii, C., Sugawara, M., Tokue, Y. & Ohya, S. (1995). Incidence of various gyrA mutants in 451 Staphylococcus aureus strains isolated in Japan, and their susceptibilities to 10 fluoroquinolones. Antimicrobial Agents and Chemotherapy 39, 1414-8.
49. Takiff, H. E., Salazar, L., Guerrero, C., Philipp, W., Huang, W. M., Kreiswirth, B. et al. (1994). Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrobial Agents and Chemotherapy 38, 773-80.
50. Vila, J., Ruiz, J., Goni, P., Marcos, A. & Jimenez-de-Anta, T. (1995). Mutation in the gyrA gene of quinolone-resistant clinical isolates of Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy 39, 1201-3.
51. Vila, J., Ruiz, J., Marco, F., Barcelo, A., Goni, P., Giralt E. et al. (1994). Association between double mutation in gyrA gene of ciprofloxacin-resistant clinical isolates of Escherichia coli and MICs. Antimicrobial Agents and Chemotherapy 38, 2477-9.
52. Wang, Y., Huang, W. M. & Taylor, D. E. (1993). Cloning and nucleotide sequence of the Campylobacter jejuni gyrA gene and characterization of quinolone resistance mutations. Antimicrobial Agents and Chemotherapy 37, 457-63.
53. Willmott, C. J. R. & Maxwell, A. (1993). A single point mutation in the DNA gyrase A protein greatly reduces binding to fluoroquinolones to the gyrase-DNA complex. Antimicrobial Agents and Chemotherapy 37, 126-7.
54. Yasuda, M., Deguchi, T., Asano, M., Ezaki, T., Saito, I. & Kawada, Y. (1995). Mutations in the DNA gyrase gyrA gene in quinolone-resistant clinical isolates of Neisseria gonorrhoeae. In Program and Abstracts of the Nineteenth International Congress of Chemotherapy, Montréal, 1995. Abstract 3416.
55. Yonezawa, M., Takahata, M., Matsubara, N., Watanabe, Y. & Narita, H. (1995). DNA gyrase gyrA mutations in quinolone-resistant clinical isolates of Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 39, 1970-2.
56. Yoshida, H., Bogaki, M., Nakamura, M. & Nakamura, S. (1990). Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrobial Agents and Chemotherapy 34, 1271-2.
57. Yoshida, H., Kojima, T., Yamagishi, J. & Nakamura, S. (1988). Quinolone-resistant mutations of the gyrA gene of Escherichia coli. Molecular and General Genetics 211, 1-7.